Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTANASDAQ:EXOZNYSE:HEXONASDAQ:IFRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$6.12+4.3%$5.39$4.09▼$17.24$130.83M0.81283,565 shs17,369 shsEXOZExozymes$14.00+0.1%$12.05$8.50▼$23.99$117.15MN/A18,691 shs7,350 shsHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsIFRXInflaRx$0.80+9.8%$1.35$0.71▼$2.82$54.38M1.57267,234 shs1.97 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+0.86%+1.38%+4.26%-25.51%-50.80%EXOZExozymes+0.07%-7.59%+24.89%-19.77%+1,399,999,900.00%HEXOHEXO0.00%0.00%0.00%0.00%0.00%IFRXInflaRx-59.86%-56.78%-40.12%-47.26%-49.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.8687 of 5 stars3.41.00.04.73.42.50.0EXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/AN/AN/AN/AIFRXInflaRx3.7906 of 5 stars4.55.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25193.87% UpsideEXOZExozymes 0.00N/AN/AN/AHEXOHEXO 0.00N/AN/AN/AIFRXInflaRx 3.00Buy$8.501,063.59% UpsideCurrent Analyst Ratings BreakdownLatest HEXO, EXOZ, ENTA, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025IFRXInflaRxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform5/8/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.004/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.003/26/2025IFRXInflaRxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/21/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/7/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$64.46M1.95N/AN/A$5.24 per share1.12EXOZExozymesN/AN/AN/AN/AN/AN/AHEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29IFRXInflaRx$129.75K377.96N/AN/A$1.89 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/4/2025 (Estimated)EXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AHEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/AIFRXInflaRx-$46.18M-$0.82N/AN/AN/A-33,362.70%-65.98%-56.86%8/14/2025 (Estimated)Latest HEXO, EXOZ, ENTA, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 million3/20/2025Q4 2024IFRXInflaRx-$0.27-$0.09+$0.18-$0.09$0.13 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.475.47EXOZExozymesN/AN/AN/AHEXOHEXO0.010.410.24IFRXInflaRxN/A5.314.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%EXOZExozymesN/AHEXOHEXO7.78%IFRXInflaRx42.39%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%EXOZExozymesN/AHEXOHEXO4.69%IFRXInflaRx16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.38 million18.37 millionOptionableEXOZExozymes298.37 millionN/AN/AHEXOHEXO1,27744.00 million41.93 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionableHEXO, EXOZ, ENTA, and IFRX HeadlinesRecent News About These CompaniesInflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28 at 11:58 PM | finanznachrichten.dePG rating: Inflarx review declares phase III bombMay 28 at 11:58 PM | bioworld.comInflaRx ditches vilobelimab Phase III trial in PGMay 28 at 11:58 PM | thepharmaletter.comInflaRx plunges on plans to halt studies into lead asset in rare skin disorderMay 28 at 11:58 PM | msn.comInflaRx Stock (IFRX) Plummets 55% on Clinical FailureMay 28 at 4:31 PM | tipranks.comInflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin DiseaseMay 28 at 11:19 AM | benzinga.comInflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust CorpMay 28 at 3:08 AM | marketbeat.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma ...May 28 at 2:16 AM | gurufocus.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28 at 1:30 AM | globenewswire.comInflaRx to Participate in Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in InflaRx (NASDAQ:IFRX)May 16, 2025 | marketbeat.comFY2025 EPS Estimates for InflaRx Raised by Cantor FitzgeraldMay 13, 2025 | marketbeat.comQ2 Earnings Forecast for InflaRx Issued By Leerink PartnrsMay 13, 2025 | marketbeat.comInflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)May 11, 2025 | sg.finance.yahoo.comOppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform RecommendationMay 9, 2025 | msn.comOppenheimer Initiates Coverage on InflaRx (IFRX) with "Outperform" Rating | IFRX ...May 8, 2025 | gurufocus.comInflaRx Reports Q1 2025 Financial Results with Reduced LossesMay 7, 2025 | tipranks.comInflaRx N.V.: InflaRx Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finanznachrichten.deInflaRx Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | globenewswire.com2IFRX : Preview: InflaRx's EarningsMay 6, 2025 | benzinga.comRaymond James Financial Inc. Makes New Investment in InflaRx (NASDAQ:IFRX)May 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Undervalued Stocks Wall Street Is Getting WrongBy Gabriel Osorio-Mazilli | May 12, 2025View 3 Undervalued Stocks Wall Street Is Getting WrongSavvy Investors Are Raising a Glass for Heineken StockBy Chris Markoch | May 18, 2025View Savvy Investors Are Raising a Glass for Heineken StockIs It Time to Buy the Dip in Novo Nordisk Stock?By Chris Markoch | May 15, 2025View Is It Time to Buy the Dip in Novo Nordisk Stock?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?By Gabriel Osorio-Mazilli | May 5, 2025View Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Is NIO Stock Set for a Comeback? Fundamentals Say YesBy Gabriel Osorio-Mazilli | May 19, 2025View Is NIO Stock Set for a Comeback? Fundamentals Say YesHEXO, EXOZ, ENTA, and IFRX Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$6.12 +0.25 (+4.26%) As of 12:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Exozymes NASDAQ:EXOZ$14.00 +0.01 (+0.07%) As of 05/28/2025 01:10 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.HEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.InflaRx NASDAQ:IFRX$0.80 +0.07 (+9.79%) As of 12:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
